New Antihypertensive PritorPlus® 80/25 And Kinzalkomb® 80/25 Approved By EU Commission
April 22nd, 2008 by samospsipsi
Bayer Schering Pharma was granted European marketing authorization for its new antihypertensive fixed dose combination drug PritorPlus® 80/25 and Kinzalkomb® 80/25 (80 mg telmisartan/25 mg hydrochlorothiazide) by the European Commission. The new formulation will be launched in Germany later this month, to be followed soon by selected countries in the EU.
More: continued here
